|
April
2006
(v06-n04) |
|
- Main Story - ViRexx (REX)
- pgs. 1-8
- Macro Market Commentary
- pgs. 9-13
- BSR
Coverage Update - pgs.
14-19
- Biotech Sector Short Interest
- pg. 20
- BSR
Model Portfolio - pg. 21
- (Full outline below...)
|
 |
|
|
April's Biotech Monthly
revisits ViRexx (AMEX:REX) an early stage biotech company with
three platform technologies. Their claim to fame is the development of
OvaRex and the platform that drug is based upon. A rpedecessor company
to ViRexx outlicensed OvaRex in 2000 for a song to United
Therapeutics (UTHR) who has advanced it through Phase III trials and
recently broke ground on a new manufacturing facility for the drug. |
 |
|
| ViRexx's new Chimigen
oncology platform technology is at least equal to that of the one they
outlicensed to United. |
Subscriber direct access |
|
| The following is an outline of this issue of
Biotech Monthly. |
|
|
- Main Story - ViRexx (AMEX:REX)
- Introduction
- Table: Company statistics
-
Disclosures
Investment Case
- Product
portfolio
- Table: ViRexx therapeutic
platforms
- AIT Platform
- Table: AIT product pipeline
- Table: Expression of target
antigen on different cancers
- Chimigen Platform
- T-ACT Platform
What can go wrong
- Macro Market Commentary -
"Strategizing the biotech landscape"
Biotech Monthly Coverage Updates
- Adolor
- BioMarin
- Dendreon
- Discovery Labs
- Conspiracy theories
- Investment case
- Forbes Medi-Tech
- Investment case
- Indevus
- Nabi
- Table: Basic facts
- Investment case
- Sonus Pharma
- YM Biosciences
Biotech Sector Short Interest BSR Model Portfolio Performance |
|
|
| |
|
|
 |
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
